Raymond James & Associates’s Nuveen Corporate Income November 2021 Target Term Fund JHB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-171,757
| Closed | -$1.61M | – | 4377 |
|
|
2021
Q3 | $1.61M | Sell |
171,757
-3,484
| -2% | -$32.7K | ﹤0.01% | 2250 |
|
|
2021
Q2 | $1.65M | Buy |
175,241
+134,131
| +326% | +$1.26M | ﹤0.01% | 2238 |
|
|
2021
Q1 | $385K | Sell |
41,110
-23,490
| -36% | -$219K | ﹤0.01% | 3197 |
|
|
2020
Q4 | $594K | Sell |
64,600
-71,815
| -53% | -$654K | ﹤0.01% | 2693 |
|
|
2020
Q3 | $1.22M | Sell |
136,415
-22,953
| -14% | -$208K | ﹤0.01% | 2059 |
|
|
2020
Q2 | $1.42M | Buy |
159,368
+55,768
| +54% | +$492K | ﹤0.01% | 1935 |
|
|
2020
Q1 | $891K | Buy |
103,600
+14,504
| +16% | +$139K | ﹤0.01% | 2060 |
|
|
2019
Q4 | $892K | Buy |
89,096
+10,602
| +14% | +$106K | ﹤0.01% | 2336 |
|
|
2019
Q3 | $776K | Sell |
78,494
-7,123
| -8% | -$70.6K | ﹤0.01% | 2349 |
|
|
2019
Q2 | $848K | Buy |
85,617
+8,498
| +11% | +$83.6K | ﹤0.01% | 2318 |
|
|
2019
Q1 | $754K | Buy |
77,119
+9,935
| +15% | +$96K | ﹤0.01% | 2373 |
|
|
2018
Q4 | $598K | Buy |
67,184
+36,583
| +120% | +$343K | ﹤0.01% | 2436 |
|
|
2018
Q3 | $292K | Sell |
30,601
-13,997
| -31% | -$134K | ﹤0.01% | 3050 |
|
|
2018
Q2 | $426K | Buy |
44,598
+20,098
| +82% | +$192K | ﹤0.01% | 2795 |
|
|
2018
Q1 | $237K | Buy |
+24,500
| New | +$238K | ﹤0.01% | 3042 |
|
Raymond James & Associates's JHB Position: Q4 2021 in Review
Raymond James & Associates sold out of Nuveen Corporate Income November 2021 Target Term Fund (JHB) in Q4 2021, closing a stake of 171,757 shares — an estimated $1.61M sold.
Raymond James & Associates first reported a position in JHB in Q1 2018 and held it in 15 quarters. The position peaked at $1.65M in Q2 2021. 0 funds tracked by Wall St. Rank hold JHB as of Q4 2021.
- Raymond James & Associates reported no remaining Nuveen Corporate Income November 2021 Target Term Fund position as of Q4 2021 after selling out during the quarter.
- Raymond James & Associates sold 171,757 Nuveen Corporate Income November 2021 Target Term Fund shares in Q4 2021, an estimated $1.61M.
- Raymond James & Associates first reported a position in Nuveen Corporate Income November 2021 Target Term Fund in Q1 2018 and held it in 15 quarters.
- Raymond James & Associates's Nuveen Corporate Income November 2021 Target Term Fund position peaked at $1.65M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Nuveen Corporate Income November 2021 Target Term Fund as of Q4 2021.
Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.